Karyopharm Therapeutics Inc. (KPTI) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Karyopharm Therapeutics Inc. (KPTI) Healthcare & Pipeline Overview

Karyopharm Therapeutics Inc. is a commercial-stage biopharmaceutical company specializing in Selective Inhibitor of Nuclear Export (SINE) compounds for cancer treatment. Its lead drug, XPOVIO, targets multiple myeloma and diffuse large B-cell lymphoma, with a focus on nuclear export mechanisms and strategic partnerships for global expansion.

What Is the Investment Thesis for KPTI?

Karyopharm Therapeutics Inc. presents a high-risk, high-reward investment opportunity. The company's primary value driver is XPOVIO (selinexor), approved for multiple myeloma and DLBCL. Revenue growth depends on expanding XPOVIO's market share and securing additional indications. Upcoming clinical trial results for other SINE compounds could serve as significant catalysts. However, the company's negative profit margin of -134.2% raises concerns about long-term financial sustainability. Successful commercialization and strategic partnerships are crucial for achieving profitability. Investors should closely monitor XPOVIO sales, clinical trial progress, and cash burn rate. The company's beta of 0.40 suggests lower volatility compared to the broader market.

Based on FMP financials and quantitative analysis

KPTI Key Highlights

XPOVIO is approved for multiple myeloma and diffuse large B-cell lymphoma, addressing critical unmet needs in these hematologic malignancies.

• Karyopharm has a license agreement with Menarini Group to commercialize NEXPOVIO in Europe and Latin America, expanding its global reach.
• The company's gross margin of 95.9% indicates strong pricing power for XPOVIO.
• Karyopharm's focus on SINE compounds represents a novel approach to cancer treatment by targeting nuclear export mechanisms.
• The company's market capitalization is $0.07 billion, reflecting its current valuation in the biopharmaceutical market.

Who Are KPTI's Competitors?

KPTI is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are KPTI's Key Strengths?

Novel SINE technology platform.

• Approved drug XPOVIO with established market presence.
• Strategic partnership with Menarini Group.
• Experienced management team.

What Are KPTI's Weaknesses?

Negative profit margin.

• Reliance on XPOVIO for revenue.
• Limited financial resources.
• Competition from established pharmaceutical companies.

What Could Drive KPTI Stock Higher?

Clinical trial results for XPOVIO in new indications.

• Regulatory decisions on potential new indications for XPOVIO.
• Expansion of XPOVIO's commercial reach in existing markets.
• Development of next-generation SINE compounds.

What Are the Key Risks for KPTI?

Financial-distress signal — its Altman Z-Score of -27.39 sits in the distress zone (elevated bankruptcy risk).

• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Clinical trial failures.
• Regulatory setbacks.
• Competition from new therapies.
• Pricing pressures.
• Dependence on XPOVIO for revenue.

What Are the Growth Opportunities for KPTI?

• Expanding XPOVIO's Indications: Karyopharm has the opportunity to expand XPOVIO's use into other hematologic malignancies and solid tumors through ongoing and planned clinical trials. Success in these trials could significantly increase XPOVIO's market potential, addressing a broader patient population. The timeline for potential approvals varies depending on the specific indication and trial outcomes, but positive data readouts in the next 12-24 months could drive substantial growth.
• Strategic Partnerships: Karyopharm can leverage strategic partnerships to expand its global reach and access new markets. The existing partnership with Menarini Group for NEXPOVIO in Europe and Latin America demonstrates the potential of this approach. Securing additional partnerships with pharmaceutical companies in other regions, such as Asia, could accelerate commercialization and increase revenue streams. These partnerships can also provide financial resources to support ongoing research and development efforts.
• Development of Next-Generation SINE Compounds: Karyopharm's pipeline of oral SINE compounds represents a significant growth opportunity. These compounds have the potential to address a wider range of cancers and other diseases. Advancing these compounds through clinical trials and securing regulatory approvals could create new revenue streams and diversify the company's product portfolio. The timeline for these developments depends on the success of clinical trials, with potential approvals in the next 3-5 years.
• Personalized Medicine Approaches: Karyopharm can explore personalized medicine approaches to identify patients who are most likely to benefit from XPOVIO and other SINE compounds. This could involve developing biomarkers to predict treatment response and tailoring treatment regimens to individual patient characteristics. Personalized medicine strategies can improve treatment outcomes and increase the value of Karyopharm's therapies.
• Acquisition or Merger: Karyopharm could be an attractive acquisition target for a larger pharmaceutical company seeking to expand its oncology portfolio. The company's SINE technology and existing approvals for XPOVIO could be valuable assets. An acquisition or merger could provide Karyopharm with access to greater resources and expertise, accelerating its growth and development. The timing of such an event is uncertain, but the company's innovative technology and market position make it a potential candidate.

What Are KPTI's Competitive Advantages?

• Proprietary SINE technology platform targeting nuclear export.
• Approved drug XPOVIO with established market presence in multiple myeloma and DLBCL.
• Strategic partnership with Menarini Group for commercialization in Europe and Latin America.
• Extensive intellectual property portfolio protecting its SINE compounds.

What Does KPTI Do?

Karyopharm Therapeutics Inc., founded in 2008 and headquartered in Newton, Massachusetts, is a commercial-stage pharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies targeting nuclear export for the treatment of cancer and other diseases. The company's core technology revolves around Selective Inhibitor of Nuclear Export (SINE) compounds, which function by binding with and inhibiting the nuclear export protein XPO1. This mechanism forces nuclear accumulation of tumor suppressor and growth regulatory proteins, disrupting cancer cell proliferation and survival. Karyopharm's lead compound, XPOVIO (selinexor), is approved in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy. It is also approved in combination with dexamethasone for adult patients with heavily pretreated multiple myeloma, and as a monotherapy for adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). These approvals mark significant milestones in addressing unmet needs in hematologic malignancies. Beyond XPOVIO, Karyopharm continues to develop a pipeline of oral SINE compounds with potential applications in various cancer types and other diseases. The company has a strategic license agreement with the Menarini Group to develop and commercialize NEXPOVIO (selinexor) for human oncology indications in Europe, including the United Kingdom, Latin America, and other countries. This partnership expands the global reach of Karyopharm's innovative therapies. Karyopharm's focus on nuclear export inhibition represents a unique approach to cancer treatment, with the potential to address a wide range of malignancies and improve patient outcomes. The company's commitment to research and development, coupled with strategic collaborations, positions it for continued growth and innovation in the biopharmaceutical industry.

What Products and Services Does KPTI Offer?

• Discovers novel Selective Inhibitor of Nuclear Export (SINE) compounds.
• Develops oral SINE compounds designed to force nuclear accumulation of tumor suppressor and growth regulatory proteins.
• Commercializes XPOVIO for the treatment of multiple myeloma.
• Commercializes XPOVIO for the treatment of relapsed or refractory diffuse large B-cell lymphoma.
• Partners with Menarini Group to develop and commercialize NEXPOVIO in Europe and Latin America.
• Conducts clinical trials to expand the indications for XPOVIO and other SINE compounds.
• Focuses on nuclear export mechanisms as a target for cancer therapy.

How Does KPTI Make Money?

• Develops and commercializes pharmaceutical products for cancer treatment.
• Generates revenue through the sale of XPOVIO.
• Out-licenses rights to its products in certain territories to partners like Menarini Group.
• Invests in research and development to expand its product pipeline.

What Industry Does KPTI Operate In?

Karyopharm Therapeutics Inc. operates within the competitive biotechnology industry, focusing on oncology. The market for cancer therapies is substantial and growing, driven by an aging population and advancements in personalized medicine. Karyopharm's SINE technology offers a unique approach compared to traditional chemotherapy and targeted therapies. Key competitors include major pharmaceutical companies developing treatments for multiple myeloma and lymphoma. The company's success depends on demonstrating the efficacy and safety of its drugs, securing regulatory approvals, and establishing strong commercial partnerships.

Who Are KPTI's Key Customers?

• Patients with multiple myeloma.
• Patients with relapsed or refractory diffuse large B-cell lymphoma.
• Healthcare providers who prescribe XPOVIO.
• Hospitals and oncology clinics that administer XPOVIO.

Company Profile

Karyopharm Therapeutics Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Newton, US. The company is led by CEO Richard A. Paulson. KPTI has traded publicly since 2013.

Karyopharm Therapeutics Inc. Financial Trajectory

Karyopharm Therapeutics Inc. (KPTI) reported $33.4M in revenue for Q2 2026, a decline of 4.7% compared to the prior quarter. The company recorded a net loss of $67.0M, with diluted EPS of $-2.32. Quarter-over-quarter revenue has been mixed, typical for a micro-cap company operating in Healthcare. Across the four most recent quarters, KPTI averaged $-3.27 in diluted EPS.

How Karyopharm Therapeutics Inc. Is Valued

Karyopharm Therapeutics Inc. carries a market capitalization of $41.3M, placing it in the micro-cap category. Relative to its peer group, KPTI's quantitative score of 18/100 is below the peer average of 76/100.

Return on equity for Karyopharm Therapeutics Inc. stands at 73.1%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -27.4%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.08 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -93.1%, the inverse of the P/E and a quick read on earnings relative to price.

Karyopharm Therapeutics Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -27.39 places it in the distress zone, a signal of elevated financial risk.

Karyopharm Therapeutics Inc. has beaten Wall Street's EPS estimate in 5 of its last 8 reported quarters — more hits than misses. Reported results have landed about 4.0% below estimates on average.

Wall Street analysts project Karyopharm Therapeutics Inc. revenue of about $133.7M for fiscal 2026, with EPS near $-4.30. The estimate reflects 4 contributing analysts.

Over the past six months, Karyopharm Therapeutics Inc. insiders filed 24 SEC Form 4 transactions — 12 sales and 12 purchases. On net that is roughly 67K shares acquired (about $327K) — insiders putting money in tends to read as conviction.

KPTI Financials

KPTI Latest News

KPTI Analyst Consensus

KPTI MoonshotScore

Common Questions About KPTI (Healthcare)

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources